HIV Genotyping and Phenotyping
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage policy for HIV genotypic and phenotypic resistance testing to guide antiretroviral therapy decisions for Blue Cross Blue Shield - Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria for HIV Genotyping and Phenotyping
Covered Indications
HIV genotyping or phenotyping MEETS COVERAGE CRITERIA in the following situations:
chunk 3
chunk 3
chunk 3
chunk 3
chunk 3
chunk 3
Not Covered
Does NOT meet coverage criteria:
chunk 4
chunk 4
Indications for resistance testing
Resistance testing recommended when ANY of the following apply:
ART should be initiated prior to results and modified if necessary once results are available (chunk 20,22)
Testing should be performed while on failing ART or within 4 weeks after stopping (chunk 22)
Genotypic testing preferred; consider proviral DNA assays for low-level viremia or undetectable RNA (chunk 25,23)
Include RT and protease genes; include integrase when INSTI resistance is a concern (chunk 22,23)
Supplementary and phenotypic testing indications
Phenotypic testing or additional assays recommended when ALL/ANY of the following apply:
Phenotypic testing may be used for investigational drugs or when genotypic interpretation is complex (chunk 23,32)
Routine baseline INSTI testing not universally recommended; order selectively (chunk 22,32)
Proviral DNA testing may miss or detect irrelevant mutations; interpret cautiously (chunk 25,32)
Assay selection
Covered when following assay-selection guidance is followed:
Current genotyping can be performed below a viral load of 1,000 copies/mL (chunk 36)
Phenotyping is adjunctive when genotype interpretation is limited (chunk 36)
Routine combined genotyping and phenotyping is explicitly excluded from coverage. The policy states that routine use of combined genotyping and phenotyping DOES NOT MEET COVERAGE CRITERIA due to insufficient published evidence supporting clinical benefit. Additionally, drug-susceptibility phenotype prediction that relies solely on genotypic comparison to databases is not covered.
Proviral (or proviral DNA) genotyping for virologically suppressed patients is not recommended for routine use when switching regimens. The policy emphasizes that genotyping is the preferred routine assay and notes that genotyping can be performed at viral loads below 1,000 copies/mL, while advising caution and selective use of alternative approaches (such as proviral DNA assays) when plasma assays are unlikely to succeed.
Laboratory-developed tests (LDTs) used for resistance testing must be validated in-house and meet regulatory requirements. LDTs are regulated by CMS as high-complexity tests under CLIA ’88 and are not FDA-cleared or -approved for clinical use; documentation of CLIA validation and high-complexity status may be required for reimbursement.
The policy designates routine combined genotyping and phenotyping testing as not medically necessary because current published literature does not demonstrate that these combined tests are required or beneficial for patient diagnosis or treatment decisions.
When laboratories use non–FDA-cleared assays, the policy requires that tests be developed, validated, and performed in-house consistent with regulatory expectations. LDTs must follow CLIA high-complexity validation processes, and payers may require evidence of such validation for reimbursement consideration.
Key Testing Thresholds and Coding Notes
Provider Actions, Documentation, and Risks
Clinical scenarios that meet coverage (and known exclusions)
HIV genotyping or phenotyping meets coverage criteria for specific clinical scenarios: treatment failure or suboptimal viral load reduction, noncompliance with therapy, acute/recent infection (within 6 months), antiretroviral‑naive patients entering treatment, all pregnant individuals in the listed situations (before ART initiation and those with detectable HIV RNA), required prior to beginning doravirine, and phenotyping for suspected multidrug resistance in treatment‑experienced patients on failing regimens. Routine combined genotyping+phenotyping and genotype‑to‑phenotype prediction are excluded from coverage.
- Covered scenarios: failed therapy, suboptimal viral load reduction, noncompliance
- Acute/recent infection (≤6 months)
- ART‑naive patients entering care
- Pregnancy: before ART initiation and for detectable HIV RNA
- Required prior to starting doravirine
- Phenotyping for suspected multidrug resistance in treatment‑experienced failing patients
Order separate INSTI genotypic assay when indicated
When integrase (INSTI) resistance is a concern (e.g., prior INSTI exposure or partner on unsuppressed/unknown viral load INSTI therapy), providers should order a specific INSTI genotypic resistance assay, which may need to be ordered separately from standard testing.
- Order INSTI-specific genotypic assay when considering an INSTI or when transmitted INSTI resistance is a concern
- INSTI assay may require separate ordering from standard RT/PR genotyping
Genotype recommended; LDT validation requirement
Genotypic testing is the preferred first-line assay in most routine clinical situations and can be performed at viral loads below 1,000 copies/mL. Laboratories using laboratory‑developed tests (LDTs) must validate those tests and perform them in‑house under CLIA high‑complexity regulations.
- Genotyping recommended in most routine clinical situations; usable at <1,000 copies/mL
- LDTs must be validated and are regulated by CMS as high‑complexity tests under CLIA '88
Timing requirement relative to ART initiation in pregnancy
Do not delay initiation of antiretroviral therapy (ART) in pregnancy while awaiting resistance test results; testing should be performed when HIV RNA is above the threshold for resistance testing but ART initiation should proceed.
- Resistance testing should be performed before starting or modifying ARV regimens when HIV RNA is ≈>500 to 1,000 copies/mL
- ART in pregnancy should not be delayed for resistance results; modify regimen when results are available
Initiate ART before assay results in pregnancy
Initiate ART in pregnant patients prior to receiving resistance assay results when clinically indicated; once resistance results are reported, modify the antiretroviral regimen if necessary based on assay findings.
- Start ART before resistance results in pregnancy to reduce transmission risk
- Modify ART when resistance assay results become available
Consider additional phenotyping for new drugs, heavily pretreated patients, and HIV‑2
Consider adding phenotypic testing for investigational or new drugs, in heavily pretreated patients with suspected multidrug resistance, and for HIV‑2 when genotypic interpretation is limited or difficult.
- Phenotyping indicated for new drugs, heavily pretreated patients, and HIV‑2
- Phenotype is adjunctive when genotypic interpretation is complex or for investigational agents
Required clinical context and documentation
Document the clinical context for resistance testing: perform resistance testing before starting or modifying ARV regimens when HIV RNA is above the resistance‑testing threshold (≈>500 to 1,000 copies/mL), and record the indication (e.g., pregnancy, virologic failure, baseline testing) in the clinical record.
- Resistance testing recommended when HIV RNA >500 to 1,000 copies/mL prior to initiating or modifying ART
- Document indication for testing (pregnancy, virologic failure, baseline, suboptimal suppression)
Include prior/current resistance results
Include all available prior and current drug‑resistance test results in the clinical record and consider them when constructing a new regimen for a patient.
- Attach or summarize prior and current resistance results in the chart when designing new regimens
- All prior/current results should be reviewed and considered (AIII)
LDT regulatory requirement
If a laboratory uses a laboratory‑developed test (LDT) for resistance assays, ensure the LDT is validated and performed in‑house; LDTs are regulated by CMS as high‑complexity tests under CLIA '88 and are not FDA‑cleared or approved.
- Maintain documentation of LDT validation and CLIA high‑complexity status for reimbursement
- LDTs are regulated by CMS under CLIA '88 and are not FDA‑cleared/approved
Coverage exclusions that may trigger denial
Routine combined use of genotyping and phenotyping is not covered; ordering combined genotypic+phenotypic testing or requesting drug‑susceptibility phenotype prediction using genotypic database comparison may lead to denial.
- Do not order routine combined genotyping and phenotyping (not covered)
- Do not rely on genotype‑to‑phenotype prediction via database comparison (not covered)
Risk when testing threshold exceeded in pregnancy
Failure to perform resistance testing in pregnant persons when HIV RNA is above the threshold for resistance testing (i.e., >500 to 1,000 copies/mL) prior to initiating or modifying ART may be inconsistent with guidance and could lead to noncompliance with reimbursement expectations.
- Perform resistance testing when HIV RNA >500 to 1,000 copies/mL in pregnancy before initiating or modifying ART when feasible
- Omitting testing in this setting may risk noncompliance with reimbursement guidance
Risk when testing threshold exceeded in virologic failure
Not performing resistance testing in persons with virologic failure and HIV RNA >1,000 copies/mL (or failing to consider testing for 500–1,000 copies/mL) may be inconsistent with recommendations and could risk denial and suboptimal therapy selection.
- Order resistance testing for virologic failure at HIV RNA >1,000 copies/mL; consider testing at 500–1,000 copies/mL despite possible assay failure
- Failure to test in virologic failure may risk denial and suboptimal care
Use of genotyping is recommended in routine situations; omission could risk denial when alternatives exist
Genotypic testing is the preferred first‑line assay in most routine clinical situations; omitting genotyping where indicated and choosing an alternative without justification may risk denial when genotyping is the recommended test.
- Use genotypic testing as first choice for routine indications and to guide initial therapy
- Document rationale if choosing phenotypic or other alternative instead of genotyping
Background
HIV is an RNA retrovirus with rapid replication and frequent emergence of resistance, which underpins the need for resistance testing. The policy recommends genotyping as the preferred assay in most routine clinical situations and specifically excludes routine combined genotyping plus phenotyping and genotype-only phenotype prediction due to limited evidence. Genotyping can be performed at viral loads below 1,000 copies/mL, while phenotypic testing is reserved for select situations such as new drugs, heavily pretreated individuals, or HIV-2 where genotypic interpretation is limited.
Definitions
Revision History
Policy adopted and effective date: adopted Avalon policy recommendation and effective 7/1/2023.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.